| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 110,901 | 53,726 | ||
| Restricted cash | 500 | 500 | ||
| Investment securities, amortized cost of 979,147 at september 30, 2025 and 1,088,561 at december 31, 2024 | 981,390 | 1,142,634 | ||
| Prepaid expenses and other current assets | 28,484 | 20,404 | ||
| Total current assets | 1,121,275 | 1,217,264 | ||
| Property and equipment, net | 14,377 | 14,670 | ||
| Operating lease right-of-use assets | 41,147 | 41,902 | ||
| Restricted cash, net of current portion | 800 | 800 | ||
| Prepaid expenses and other assets, net of current portion | 18,432 | 14,938 | ||
| Total assets | 1,196,031 | 1,289,574 | ||
| Accounts payable and accrued expenses | 33,674 | 38,086 | ||
| Accrued compensation and related expenses | 32,398 | 21,796 | ||
| Deferred revenue | 1,642 | 1,904 | ||
| Operating lease liabilities | 6,441 | 6,610 | ||
| Total current liabilities | 74,155 | 68,396 | ||
| Operating lease liabilities, non-current | 42,703 | 43,326 | ||
| Deferred revenue, non-current | 4,110 | 3,992 | ||
| Other liabilities | 2,894 | 2,334 | ||
| Total liabilities | 123,862 | 118,048 | ||
| Common stock and paid-in capital, 0.001 par 200,000 shares authorized 94,548 shares issued and outstanding at september 30, 2025 92,926 shares issued and outstanding at december 31, 2024 | 2,364,699 | 2,334,538 | ||
| Stock held in trust | - | 112 | ||
| Accumulated other comprehensive income | 2,194 | 1,621 | ||
| Accumulated deficit | -1,294,612 | -1,164,521 | ||
| Stock held in trust | 112 | - | ||
| Total stockholders equity | 1,072,169 | 1,171,526 | ||
| Total liabilities and stockholders equity | 1,196,031 | 1,289,574 | ||
Crinetics Pharmaceuticals, Inc. (CRNX)
Crinetics Pharmaceuticals, Inc. (CRNX)